镁化合物对合并慢性阻塞性肺病的动脉高血压患者的综合治疗效果

T. Nazaruk
{"title":"镁化合物对合并慢性阻塞性肺病的动脉高血压患者的综合治疗效果","authors":"T. Nazaruk","doi":"10.25040/lkv2023.03-04.024","DOIUrl":null,"url":null,"abstract":"Introduction. The combination of arterial hypertension and chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular complications. During exacerbations of COPD, almost every second patient has hypomagnesemia. In particular, intravenous magnesium (Mg) administration in stable patients with COPD has been shown to improve lung function and respiratory muscle strength. Numerous publications report positive impact of various magnesium compounds causing the decrease in blood pressure. The above justifies the expediency of further studying the effectiveness of magnesium compounds in hypertension with concomitant COPD. The aim of the study. To determine the effectiveness of a fixed combination of magnesium and vitamin B6 in the complex treatment of patients with hypertension accompanied by COPD. Materials and methods. 60 patients with stage II hypertension and concomitant COPD were subjected to clinical examination. The data of office and home blood pressure monitoring was supplemented with spirometry, electrocardiography, laboratory tests and results of EQ-5D, mMRC, CAT. Results. Treatment with the additional fixed combination of magnesium and vitamin B6 (MgB6) in patients with hypertension accompanied by COPD reduced complaints and improved quality of life from (52.6 ± 3.4) points to (74.2 ± 3.8) points (р less than 0.001). In 25 (83.3 ± 6.8 %) patients treated with MgB6, it was possible to achieve the target blood pressure; while in the control group similar results were obtained only in (26.6 ± 8.1%) (р less than 0.001). Aplication of a fixed MgB6 combination in patients with hypertension and COPD reduced the frequency of tachycardia from (23.3 ± 7.7)% to (3.3 ± 3.3)% (р less than 0.02), and frequency of supraventricular extrasystole from (36.7 ± 8.8)% to (13.3 ± 6.2)% (р less than 0.05). Improvement of repolarization processes was observed in (46.7 ± 9.1)% of patients who additionally received FC MgB6 and only in (16.7 ± 6.8)%, (p less than 0.02) of the control group. Complex treatment with the addition of a fixed combination of MgB6 contributed to the improvement of spirometry parameters: FEV1 – from (55.9 ± 3.0) to (65.8 ± 4.4) (р less than 0.05) and FEV1/FVC – from (62.3 ± 3.1) to (71.6 ± 3.4) (р less than 0.05). Conclusion. Complex treatment of patients with arterial hypertension and chronic obstructive pulmonary disease, in which a fixed combination of magnesium and vitamin B6 is added to the basic treatment, improved the clinical course of comorbidities, bioelectrical activity of the heart, reduced blood pressure, improved spirometry and quality of life.","PeriodicalId":279640,"journal":{"name":"Lviv clinical bulletin","volume":"40 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effectiveness of magnesium compounds in the complex treatment of patients with arterial hypertension with concomitant chronic obstructive pulmonary disease\",\"authors\":\"T. Nazaruk\",\"doi\":\"10.25040/lkv2023.03-04.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. The combination of arterial hypertension and chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular complications. During exacerbations of COPD, almost every second patient has hypomagnesemia. In particular, intravenous magnesium (Mg) administration in stable patients with COPD has been shown to improve lung function and respiratory muscle strength. Numerous publications report positive impact of various magnesium compounds causing the decrease in blood pressure. The above justifies the expediency of further studying the effectiveness of magnesium compounds in hypertension with concomitant COPD. The aim of the study. To determine the effectiveness of a fixed combination of magnesium and vitamin B6 in the complex treatment of patients with hypertension accompanied by COPD. Materials and methods. 60 patients with stage II hypertension and concomitant COPD were subjected to clinical examination. The data of office and home blood pressure monitoring was supplemented with spirometry, electrocardiography, laboratory tests and results of EQ-5D, mMRC, CAT. Results. Treatment with the additional fixed combination of magnesium and vitamin B6 (MgB6) in patients with hypertension accompanied by COPD reduced complaints and improved quality of life from (52.6 ± 3.4) points to (74.2 ± 3.8) points (р less than 0.001). In 25 (83.3 ± 6.8 %) patients treated with MgB6, it was possible to achieve the target blood pressure; while in the control group similar results were obtained only in (26.6 ± 8.1%) (р less than 0.001). Aplication of a fixed MgB6 combination in patients with hypertension and COPD reduced the frequency of tachycardia from (23.3 ± 7.7)% to (3.3 ± 3.3)% (р less than 0.02), and frequency of supraventricular extrasystole from (36.7 ± 8.8)% to (13.3 ± 6.2)% (р less than 0.05). Improvement of repolarization processes was observed in (46.7 ± 9.1)% of patients who additionally received FC MgB6 and only in (16.7 ± 6.8)%, (p less than 0.02) of the control group. Complex treatment with the addition of a fixed combination of MgB6 contributed to the improvement of spirometry parameters: FEV1 – from (55.9 ± 3.0) to (65.8 ± 4.4) (р less than 0.05) and FEV1/FVC – from (62.3 ± 3.1) to (71.6 ± 3.4) (р less than 0.05). Conclusion. Complex treatment of patients with arterial hypertension and chronic obstructive pulmonary disease, in which a fixed combination of magnesium and vitamin B6 is added to the basic treatment, improved the clinical course of comorbidities, bioelectrical activity of the heart, reduced blood pressure, improved spirometry and quality of life.\",\"PeriodicalId\":279640,\"journal\":{\"name\":\"Lviv clinical bulletin\",\"volume\":\"40 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lviv clinical bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25040/lkv2023.03-04.024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lviv clinical bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25040/lkv2023.03-04.024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介动脉高血压和慢性阻塞性肺病(COPD)并发症会增加心血管并发症的风险。在慢性阻塞性肺病恶化期间,几乎每两名患者中就有一人出现低镁血症。特别是,对病情稳定的慢性阻塞性肺病患者静脉注射镁(Mg)已被证明可改善肺功能和呼吸肌力量。大量文献报道了各种镁化合物对降低血压的积极影响。因此,有必要进一步研究镁化合物对合并慢性阻塞性肺病的高血压患者的疗效。研究目的确定镁和维生素 B6 的固定组合在高血压合并慢性阻塞性肺病患者的综合治疗中的有效性。材料和方法对 60 名 II 期高血压并伴有慢性阻塞性肺病的患者进行临床检查。办公室和家庭血压监测数据与肺活量测定、心电图、实验室检查和 EQ-5D、mMRC、CAT 的结果相辅相成。结果显示对伴有慢性阻塞性肺病的高血压患者额外使用镁和维生素 B6(MgB6)的固定组合进行治疗,减少了患者的抱怨,生活质量从(52.6 ± 3.4)分提高到(74.2 ± 3.8)分(р小于 0.001)。25 名(83.3 ± 6.8 %)接受过 MgB6 治疗的患者可以达到目标血压;而在对照组中,只有(26.6 ± 8.1 %)的患者获得了类似的结果(р 小于 0.001)。在高血压和慢性阻塞性肺病患者中应用固定 MgB6 组合,可将心动过速的发生率从(23.3 ± 7.7)% 降至(3.3 ± 3.3)%(р 小于 0.02),室上性期外收缩的发生率从(36.7 ± 8.8)% 降至(13.3 ± 6.2)%(р 小于 0.05)。在额外接受 FC MgB6 治疗的患者中,有(46.7 ± 9.1)% 的人的再极化过程得到了改善,而在对照组中,只有(16.7 ± 6.8)% 的人的再极化过程得到了改善(P 小于 0.02)。添加 MgB6 固定组合的复合治疗有助于改善肺活量参数:FEV1 - 从(55.9 ± 3.0)增至(65.8 ± 4.4)(р小于 0.05),FEV1/FVC - 从(62.3 ± 3.1)增至(71.6 ± 3.4)(р小于 0.05)。结论动脉高血压和慢性阻塞性肺疾病患者的复合治疗,即在基本治疗的基础上添加镁和维生素 B6 的固定组合,可改善合并症的临床过程、心脏的生物电活动、降低血压、改善肺活量和生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The effectiveness of magnesium compounds in the complex treatment of patients with arterial hypertension with concomitant chronic obstructive pulmonary disease
Introduction. The combination of arterial hypertension and chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular complications. During exacerbations of COPD, almost every second patient has hypomagnesemia. In particular, intravenous magnesium (Mg) administration in stable patients with COPD has been shown to improve lung function and respiratory muscle strength. Numerous publications report positive impact of various magnesium compounds causing the decrease in blood pressure. The above justifies the expediency of further studying the effectiveness of magnesium compounds in hypertension with concomitant COPD. The aim of the study. To determine the effectiveness of a fixed combination of magnesium and vitamin B6 in the complex treatment of patients with hypertension accompanied by COPD. Materials and methods. 60 patients with stage II hypertension and concomitant COPD were subjected to clinical examination. The data of office and home blood pressure monitoring was supplemented with spirometry, electrocardiography, laboratory tests and results of EQ-5D, mMRC, CAT. Results. Treatment with the additional fixed combination of magnesium and vitamin B6 (MgB6) in patients with hypertension accompanied by COPD reduced complaints and improved quality of life from (52.6 ± 3.4) points to (74.2 ± 3.8) points (р less than 0.001). In 25 (83.3 ± 6.8 %) patients treated with MgB6, it was possible to achieve the target blood pressure; while in the control group similar results were obtained only in (26.6 ± 8.1%) (р less than 0.001). Aplication of a fixed MgB6 combination in patients with hypertension and COPD reduced the frequency of tachycardia from (23.3 ± 7.7)% to (3.3 ± 3.3)% (р less than 0.02), and frequency of supraventricular extrasystole from (36.7 ± 8.8)% to (13.3 ± 6.2)% (р less than 0.05). Improvement of repolarization processes was observed in (46.7 ± 9.1)% of patients who additionally received FC MgB6 and only in (16.7 ± 6.8)%, (p less than 0.02) of the control group. Complex treatment with the addition of a fixed combination of MgB6 contributed to the improvement of spirometry parameters: FEV1 – from (55.9 ± 3.0) to (65.8 ± 4.4) (р less than 0.05) and FEV1/FVC – from (62.3 ± 3.1) to (71.6 ± 3.4) (р less than 0.05). Conclusion. Complex treatment of patients with arterial hypertension and chronic obstructive pulmonary disease, in which a fixed combination of magnesium and vitamin B6 is added to the basic treatment, improved the clinical course of comorbidities, bioelectrical activity of the heart, reduced blood pressure, improved spirometry and quality of life.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信